Biogen Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?

Managing SG&A Costs: Biogen Inc. vs. Soleno Therapeutics, Inc.

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Biogen Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.

Biogen Inc., a leader in biotechnology, has consistently maintained high SG&A expenses, averaging around $2.3 billion annually from 2014 to 2023. Despite this, Biogen's expenses have shown a steady increase, peaking at approximately $2.67 billion in 2021, reflecting a 38% rise from 2014.

Conversely, Soleno Therapeutics, Inc., a smaller player, has managed to keep its SG&A costs significantly lower, averaging just over $8 million annually. However, Soleno's expenses have also seen a notable increase, with a 362% rise from 2014 to 2023, reaching $13.5 million.

This data highlights the diverse strategies employed by these companies in managing operational costs, with Biogen focusing on scale and Soleno on efficiency.